Moderna Inc (MRNA)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.30 | 1.32 | 1.34 | 1.31 | 1.33 | 1.45 | 1.29 | 1.28 | 1.35 | 1.45 | 1.45 | 1.62 | 1.74 | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 |
Moderna Inc has consistently maintained a very strong solvency position, as reflected in its solvency ratios. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have all been at 0.00 across all reporting periods up to December 31, 2024. This indicates that the company has not taken on any long-term debt relative to its total assets, capital, or equity, suggesting a low financial risk and a healthy balance sheet structure.
The Financial leverage ratio, which measures the extent of a company's financial leverage, has shown a declining trend over the years. Starting at 1.26 on March 31, 2020, it decreased steadily to 1.30 by December 31, 2024. This decline indicates that Moderna Inc has been relying less on debt financing and moving towards a more conservative capital structure, which can enhance its financial stability and resilience to economic uncertainties.
Overall, the solvency ratios of Moderna Inc demonstrate a robust financial position with minimal debt obligations, prudent leverage levels, and a sound capital structure, positioning the company well for potential future growth and investment opportunities.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -149.29 | -99.96 | -156.21 | -138.20 | -104.58 | -57.14 | 17.85 | 153.03 | 324.83 | 530.00 | 744.76 | 774.33 | 738.72 | 491.33 | 267.30 | 58.01 | -74.31 | -70.41 | -67.97 | -74.21 |
Interest coverage ratio measures a company's ability to cover its interest expenses with its earnings before interest and taxes (EBIT). A higher interest coverage ratio indicates the company is more capable of meeting its interest obligations.
Analyzing Moderna Inc's interest coverage ratio data from March 2020 to December 2024, we observe a significant improvement in the company's ability to cover its interest expenses. The ratio started at negative values, indicating that the company's EBIT was insufficient to cover its interest expenses. However, by March 2021, the interest coverage ratio turned positive, indicating a positive trend in the company's financial health.
From June 2021 to December 2022, Moderna Inc's interest coverage ratio showed a substantial increase, reaching its peak at 774.33 in March 2022. This significant improvement suggests that the company's EBIT was more than sufficient to cover its interest expenses during this period.
Subsequently, the interest coverage ratio started declining from June 2022 to December 2024. Despite the declining trend, the ratio remained positive, indicating that Moderna Inc still had a healthy ability to cover its interest payments, although at a decreasing rate.
Overall, the trend in Moderna Inc's interest coverage ratio reflects an initial struggle followed by a remarkable improvement and then a gradual decline. The company's ability to cover its interest expenses improved significantly over the period under review, suggesting a better financial position and a reduced risk of defaulting on its debt obligations.